We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Biophytis SA (BPTS) ADS

Sell:$0.1 Buy:$1.64 Change: No change
Market closed |  Prices as at close on 23 June 2022 | Switch to live prices |
Sell:$0.1
Buy:$1.64
Change: No change
Market closed |  Prices as at close on 23 June 2022 | Switch to live prices |
Sell:$0.1
Buy:$1.64
Change: No change
Market closed |  Prices as at close on 23 June 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.

Contact details

Address:
14 avenue de l'Opera
PARIS
75001
France
Telephone:
+33 (1) 41836600
Website:
www.biophytis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BPTS
ISIN:
US09076G1040
Market cap:
$18.29 million
Shares in issue:
135.95 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Stanislas Veillet
    Chairman of the Board, Chief Executive Officer
  • Philippe Rousseau
    Chief Financial Officer
  • Waly Dioh
    Chief Clinical Operating Officer
  • Pierre Dilda
    Chief Scientific Officer
  • Benoit Canolle
    Chief Business Officer
  • Rob Maanen
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.